E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Moderate to severe systemic lupus erythematosus |
Lupus eritematoso sistémico de moderado a grave. |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Immune System Diseases [C20] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10042945 |
E.1.2 | Term | Systemic lupus erythematosus |
E.1.2 | System Organ Class | 10028395 - Musculoskeletal and connective tissue disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the efficacy of 6 months cenerimod treatment given at 4 different dose levels (0.5, 1, 2, and 4 mg once daily) on disease activity in adult subjects with moderate to severe SLE concurrently receiving background therapy |
Evaluar la eficacia de un tratamiento con cenerimod durante 6 meses administrado en 4 niveles de dosis diferentes (0,5, 1, 2 y 4 mg una vez al día) sobre la actividad de la enfermedad en pacientes adultos con LES de moderado a grave que reciben simultáneamente tratamiento de base. |
|
E.2.2 | Secondary objectives of the trial |
To evaluate over 6 months in adult subjects with moderate to severe SLE concurrently receiving background therapy: • the safety and tolerability of cenerimod treatment • the effect of cenerimod treatment on quality of life and fatigue using relevant patient reported outcome (PRO) instruments • the effect of cenerimod treatment on SLE biomarkers |
Evaluar los siguientes aspectos durante un periodo de 6 meses en pacientes adultos con LES de moderado a grave que reciben simultáneamente tratamiento de base: • La seguridad y tolerabilidad del tratamiento con cenerimod. • El efecto del tratamiento con cenerimod en la calidad de vida y en la fatiga usando los instrumentos de resultados percibidos por el paciente (RPP) pertinentes. • El efecto del tratamiento con cenerimod en biomarcadores de LES. |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
At randomization, approximately 125 subjects will be assigned to the echocardiography ancillary study through the IRT system. The echocardiography ancillary study will run concurrently with the main study. Subjects assigned into the echocardiography ancillary study will undergo an echocardiography assessment at Month 6, in addition to echocardiography assessments that will be performed for all subjects during the screening period. |
Aproximadamente 125 sujetos serán asignados al estudio de ecocardiograma mediante el sistéma IRT durante la aleatorización. El estudio de ecocardiograma se llevará a cabo a la vez que el estudio principal. Se realizará un ecocardiograma adicional a los sujetos asignadoas en el mes 6, además de los demás ecocardiogramas que se realizarán a todos los sujetos durante el periodo de screening. |
|
E.3 | Principal inclusion criteria |
- Signed ICF prior to any study-mandated procedure - Diagnosis of SLE made at least 6 months prior to Screening, by fulfilling at least 4 of the 11 criteria for SLE as defined by the American College of Rheumatology (ACR) criteria - A mSLEDAI-2K score ≥ 6 of at least 2 points for musculoskeletal or mucocutaneous manifestations (i.e., myositis, arthritis, rash, alopecia, mucosal ulcers). The mSLEDAI-2K score does not take into account “leukopenia” - Currently treated with stable doses of one or more of the following background medications: • NSAIDs • Anti-malarials (≤ 400 mg/day hydroxychloroquine, ≤ 500 mg/day chloroquine, ≤ 100 mg/day quinacrine) • Mycophenolate mofetil (≤ 2 g/day) • Azathioprine (≤ 2 mg/kg/day) • Methotrexate (≤ 20 mg/week) • Corticosteroids (≤ 40 mg/day prednisone or equivalent) • Belimumab (≤10 mg/kg every 4 weeks) - History or presence of positive autoantibodies measured by central laboratory defined as follows: (a) Positive antinuclear antibody (ANA) test measured by immunofluorescence assay (IFA) with titre ≥1:80; AND/OR (b) positive anti-double stranded deoxyribonucleic acid (anti-dsDNA) antibodies with titre ≥30 IU/mL - Women of childbearing potential (WOCBP): • Must have a negative serum pregnancy test at Screening • Must agree to undertake monthly urine pregnancy tests during the study • Must use highly effective methods of contraception from the screening visit until 4 months after taking the last dose of study treatment |
-FCI firmado previo a cualquier procedimiento que se incluya en el estudio -diagnóstico de LES realizado con una antelación de al menos 6 meses antes de la selección y que cumpla al menos cuatro de los 11 criterios del LES, según el American College of Rheumatology (ACR, Colegio Estadounidense de Reumatología). -Una puntuación del SLEDAI-2K modificado ≥ 6 de al menos 2 puntos en cuanto a manifestaciones musculoesqueléticas o mucocutáneas (es decir, miositis, artritis, erupción cutánea, alopecia, úlceras en las mucosas). La puntuación del SLEDAI-2K modificado no tiene en cuenta "leucopenia". -Actualmente en tratamiento con dosis estables de una o más de las siguientes medicaciones de base: • Antiinflamatorios no esteroideos (AINE), • Antipalúdicos (≤ 400 mg/día de hidroxicloroquina, ≤ 500 mg/día de cloroquina, ≤ 100 mg/día de quinacrina) • Micofenolato de mofetilo (≤ 2 g/día), • Azatioprina (≤ 2 mg/kg/día), • Metotrexato (≤ 20 mg/semana), • Corticoesteroides (≤ 40 mg/día de prednisona o equivalente), • Belimumab (≤ 10 mg/kg cada 4 semanas) -Historia o presencia de anticuerpos positivos medidos por un laboratorio central definida del siguiente modo (en base a la muestra de selección): (a) análisis AAN positivo medido por ensayo por inmunofluorescencia con valor ≥ 1:80; Y/O (b) anticuerpos anti-ADNbc positivos con valor ≥ 30 UI/ml. -Mujeres en edad fértil (MEEF): • Deben haberse realizado una prueba de embarazo con resultado negativo durante la selección. • Se comprometerán a someterse a pruebas de embarazo en orina mensuales durante el estudio. • Deberán utilizar métodos anticonceptivos eficaces desde la visita de selección hasta transcurridos 4 meses tras la última dosis del tratamiento del estudio. |
|
E.4 | Principal exclusion criteria |
- Active lupus nephritis or a renal biopsy demonstrating immune complex mediated glomerulonephritis compatible with lupus nephritis. - CNS lupus and severe forms of vasculitis requiring systemic immunosuppressive treatment. - A diagnosis of mixed connective tissue disease or any history of overlap syndromes of SLE with rheumatoid arthritis, erosive arthritis, scleroderma or autoimmune hepatitis. - History or presence of Mobitz type II or third-degree atrioventricular block, sick sinus syndrome, symptomatic bradycardia or syncope associated with cardiac disorders. - Subjects who experienced myocardial infarction, unstable angina pectoris, stroke, transient ischemic attack, vascular thrombosis, decompensated heart failure requiring hospitalization, or heart failure defined by the New York Heart Association Class III/IV within six months prior to Screening. - An elevated QT corrected for HR on the basis of Fridericia’s formula interval of > 470 ms (females) / > 450 ms (males). - History or presence of severe respiratory disease or pulmonary fibrosis. - Active or latent tuberculosis . - Ongoing bacterial, viral or fungal infection that is of clinical concern in the judgment of the investigator or history of any serious infection. - Subjects who have congenital or acquired severe immunodeficiency or known HIV infection or positive HIV testing. - Presence of macular edema or active uveitis. - Type 1 or 2 diabetes that is poorly controlled according to investigator judgment, or diabetes complicated with organ involvement such as diabetic nephropathy or retinopathy. - Significant hematology abnormality: Lymphocyte count < 800 /μL (0.8 × 10e9/L); hemoglobin < 9 g/dL; WBC count < 2500/μL (2.5 × 10e9/L) or platelets < 75000/μL (75 × 10e9/L). - Estimated glomerular filtration rate < 60 mL/min/1.73 m2. - Known allergy to S1P receptor modulators or any of the cenerimod formulation excipients |
-Nefritis en el lupus activa o una biopsia renal que demuestre una glomerulonefritis mediada por inmunocomplejos compatible con nefritis en el lupus. -Lupus en el sistema nervioso central (SNC) y formas graves de vasculitis que requieren tratamiento sistémico inmunosupresor. -Diagnóstico de enfermedad mixta del tejido conjuntivo o antecedentes de síndrome de superposición de LES con artritis reumatoide, artritis erosiva, esclerodermia o hepatitis autoinmunitaria. -Antecedentes o presencia de Mobitz de tipo II o bloqueo auriculoventricular de tercer grado, síndrome del nodo sinusal enfermo, bradicardia sintomática o síncope asociados con enfermedades cardíacas. -Pacientes que hayan sufrido infarto de miocardio, angina de pecho inestable, derrame cerebral, ataque isquémico transitorio, trombosis vascular, insuficiencia cardíaca descompensada que requiere hospitalización o insuficiencia cardíaca de las clases III-IV de la New York Heart Association durante los seis meses anteriores a la selección. -Un QT corregido para frecuencia cardíaca (FC) elevado según el intervalo de la fórmula de Fridericia (QTcF) de > 470 ms (mujeres) / > 450 ms (hombres). -Antecedentes o presencia de enfermedad respiratoria grave o fibrosis pulmonar. -Tuberculosis activa o latente. -Infección bacteriana, vírica o fúngica en curso de interés clínico a juicio del investigador o antecedentes de infecciones graves. -Pacientes con inmunodeficiencia grave congénita o adquirida o infección por VIH conocida o pruebas del VIH positivas. -Presencia de edema macular o de uveitis activa. -Diabetes de tipo 1 o 2 mal controlada a juicio del investigador o diabetes complicada con implicación de órganos, tal como nefropatía o retinopatía diabética. -Anormalidad hematológica significativa: Recuento de linfocitos < 800 /μL (0,8 × 109/l); hemoglobina < 9 g/dl; recuento de leucocitos < 2500/μL (2,5 × 109/l) o plaquetas < 75 000/μL (75 × 109/l). -Tasa de filtración glomerular estimada < 60 ml/min/1,73 m2. -Alergia conocida a los moduladores del receptor esfingosina-1-fosfato (S1P) o a cualquiera de los excipientes de la fórmula de cenerimod. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Change from baseline to Month 6 in the mSLEDAI-2K score |
Cambio desde visita basal a mes 6 en la puntuación SLEDAI-2K modificado. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
From baseline to Month 6 |
Desde visita basal a mes 6. |
|
E.5.2 | Secondary end point(s) |
Response on SRI4 at Month 6 as compared to baseline Percent of subjects with no new organ system affected as defined by one or more BILAG A or 2 or more BILAG B items as compared with baseline at Month 6 |
Respuesta del Índice de respuesta del LES (SRI) 4 en el mes 6 en comparación con los valores iniciales Porcentaje de pacientes sin afectación de nuevos órganos, definida por uno o más elementos del BILAG A o bien 2 o más elementos del BILAG B, en comparación con los valores iniciales del mes 6. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
At month 6 after study treatment initiation |
Mes 6 tras el inicio del tratamiento con la medicación en estudio. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Biomarkers, tolerability, patient reported outcomes |
Biomarcadores, tolerabilidad y resultados reportados por el paciente. |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 5 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 5 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 73 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Bulgaria |
China |
Czech Republic |
France |
Georgia |
Germany |
Hong Kong |
Hungary |
Israel |
Italy |
Lithuania |
Mexico |
Poland |
Romania |
Russian Federation |
Spain |
Taiwan |
Thailand |
Turkey |
Ukraine |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LVLS |
Última visita del último paciente. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 32 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial months | 32 |